Haha....FEAR....SELL....ahhhhhh-hahaha! Nice job jepro/bb! Really good job of bashing. Fact is AST two dendritic vaccines getting good results so far, and same goes for their spine OPC1.
Not getting my shares bozo!
Should creep up to ten prior to PanC-DX release and double from there once these cancer cancer diagnostic products start to hit the market in late 2015. Great short-med-long term investment!
Time to buy and hold. Market cap 400k, subsidiary AST exploding, partnerships happening, low hanging fruit blooming... no debt, 30mil cash, multiple stem conferences next few months, clinical trial results for cartilage regen cosmetic surgery in 2015 and more clinical trials programs to start, BlacRock recently increased investments....dream investment!
Side note, icel/GE deal fell through, ICEL gave up on their ips ip and sold to Fujifilm of all companies.
2012 ICELL deal:
NEW YORK (GenomeWeb News) – GE Healthcare Life Sciences and Cellular Dynamics today announced a licensing deal allowing CDI to develop, manufacture, and sell cellular assays and models derived from induced pluripotent stem cells for drug discovery and toxicity screening.
2015 BTX deal:
ALAMEDA, Calif.--(BUSINESS WIRE)--BioTime, Inc. (NYSE MKT: BTX) today announced that its subsidiary ES Cell International Pte. Ltd. (“ESI”) and GE Healthcare (GEHC) have signed a set of license agreements through which GEHC received rights to ESI’s stem cell patents and ESI received rights to stem cell patents controlled by GEHC, in both cases for the development of cellular assays and models derived from stem cells for use in drug discovery and toxicity screening. In addition, the agreements give GEHC the right to grant sub-licenses to the ESI patent portfolio and, in certain circumstances, ESI may further sublicense its rights for the purpose of marketing stem cell-derived products. Financial terms were not disclosed.
Carolyn, since you are a newbie thought I'd let you know the buy and bash list includes jet pro, realtruf, baltbear and usually anyone who seriously converses with them. My advice to you is to put these ID's on 'ignore' since they will lie at all cost.
This is the result for companies who are first to jump into such a new and fast developing field. ICEL was in a sense lucky to brake even. Biotime on the other hand is slowly building their regen program based on a monopoly of hESC ip which is fast becoming the gold standard thanks to big data and genetic authentication.
GE partnership last month confirms this!
CUR, STEM, GERN, KOOL, CYTX, ASTM, ACTC, TNGN, BCLI..
All stem cell companies I know pale in comparison.
OncoCyte PanC patents to be confirmed, that will be huge factor. Technically genes can't be pAtented, but the proprietary gene marker method for testing can be. Once these patents come through all out buying blitz.